Preclinical Efficacy of a PSMA-Targeted Actinium-225 Conjugate (225Ac-Macropa-Pelgifatamab): A Targeted Alpha Therapy for Prostate Cancer

Post time 5 day(s) ago

journal：Clinical Cancer Research

Authors：Christoph A. Schatz; Sabine Zitzmann-Kolbe; Ingrid Moen; Monika Klotz; Shankari Nair; Stefan Stargard; Roger M. Bjerke; Katrine Wickstrm Biseth; Yuan Zeng Feng; Brd Indrevoll; Veronique Cruciani; Jenny Karlsson; Bernard Haendler; Carsten H. Nielsen; Maria Z. Alfsen; Stefanie Hammer; Hartwig Hennekes; Alan Cuthbertson; Urs B. Hagemann; smund Larsen

Published date：2024-6-3

DOI：10.1158/1078-0432.ccr-23-3746

PDF link：https://aacrjournals.org/clincan ... 820/ccr-23-3746.pdf

Article link：https://doi.org/10.1158/1078-0432.ccr-23-3746

Article Source：American Association for Cancer Research (AACR)。

Remark：

Post time 5 day(s) ago

: This post has been completed
Completed attachments will be deleted within 24 hours.

[AACR] Preclinical Efficacy of a PSMA-Targeted Actinium-225 Conjugate (225Ac-Macropa-Pelgifatamab): A Targeted Alpha Therapy for Prostate Cancer

Best Answer

Same Category

Latest Reply

Announcement

Daily Top Contributors

[AACR] Preclinical Efficacy of a PSMA-Targeted Actinium-225 Conjugate (225Ac-Macropa-Pelgifatamab): A Targeted Alpha Therapy for Prostate Cancer Copy